The role of cytochrome P450 2D6 in the metabolism of moclobemide.

Article Details

Citation

Copy to clipboard

Hartter S, Dingemanse J, Baier D, Ziegler G, Hiemke C

The role of cytochrome P450 2D6 in the metabolism of moclobemide.

Eur Neuropsychopharmacol. 1996 Aug;6(3):225-30.

PubMed ID

8880082 [ View in PubMed

]

Abstract

The metabolic fate of moclobemide (Ro 11-1163), a new reversible and selective inhibitor of monoamine oxidase type A (MAO-A), has been assessed in a pilot study in 2 debrisoquine poor metabolizers (PM) and 4 extensive metabolizers (EM) after multiple oral dosings of moclobemide with and without co-medication of dextromethorphan. Absorption and disposition parameters were not different between PM and EM. Concurrent application of dextromethorphan, a selective substrate of CYP2D6, did not affect the pharmacokinetics of moclobemide. These results indicate that the cytochromal isoenzyme CYP2D6 does not play a major role in the metabolic degradation of moclobemide. Limited CYP2D6 activities because of a genetic defect or co-medications with CYP2D6 substrates should therefore not give rise to elevated moclobemide blood levels.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Moclobemide	Cytochrome P450 2D6	Protein	Humans	Unknown	Substrate Inhibitor	Details